Vertex Net Interest Income vs Other Operating Expenses Analysis
VRTX Stock | USD 402.14 9.33 2.38% |
Vertex Pharmaceuticals financial indicator trend analysis is much more than just breaking down Vertex Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Vertex Pharmaceuticals is a good investment. Please check the relationship between Vertex Pharmaceuticals Net Interest Income and its Other Operating Expenses accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.
Net Interest Income vs Other Operating Expenses
Net Interest Income vs Other Operating Expenses Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Vertex Pharmaceuticals Net Interest Income account and Other Operating Expenses. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Vertex Pharmaceuticals' Net Interest Income and Other Operating Expenses is 0.82. Overlapping area represents the amount of variation of Net Interest Income that can explain the historical movement of Other Operating Expenses in the same time period over historical financial statements of Vertex Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Vertex Pharmaceuticals' Net Interest Income and Other Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Interest Income of Vertex Pharmaceuticals are associated (or correlated) with its Other Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Operating Expenses has no effect on the direction of Net Interest Income i.e., Vertex Pharmaceuticals' Net Interest Income and Other Operating Expenses go up and down completely randomly.
Correlation Coefficient | 0.82 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Net Interest Income
The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Vertex Pharmaceuticals. It is also known as Vertex Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most indicators from Vertex Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Vertex Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.At this time, Vertex Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 798.2 M in 2024, whereas Discontinued Operations is likely to drop (861.8 K) in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 6.7B | 7.9B | 8.6B | 9.0B | Total Revenue | 7.6B | 8.9B | 9.8B | 10.3B |
Vertex Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Vertex Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Vertex Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 8.3B | 11.8B | 13.4B | 18.2B | 22.7B | 23.9B | |
Short Long Term Debt Total | 577.4M | 581.5M | 556.7M | 561M | 808.4M | 848.8M | |
Other Current Liab | 1.0B | 1.2B | 1.5B | 1.9B | 2.9B | 3.1B | |
Total Current Liabilities | 1.2B | 1.6B | 1.9B | 2.4B | 3.5B | 3.7B | |
Total Stockholder Equity | 6.1B | 8.7B | 10.1B | 13.9B | 17.6B | 18.5B | |
Property Plant And Equipment Net | 745.1M | 958.5M | 1.1B | 1.1B | 1.5B | 1.5B | |
Net Debt | (2.5B) | (5.4B) | (6.2B) | (9.9B) | (9.6B) | (9.1B) | |
Retained Earnings | (1.9B) | 858.7M | 3.2B | 6.5B | 10.1B | 10.6B | |
Cash | 3.1B | 6.0B | 6.8B | 10.5B | 10.4B | 10.9B | |
Non Current Assets Total | 3.7B | 3.9B | 4.4B | 5.5B | 8.6B | 9.0B | |
Non Currrent Assets Other | 326.9M | 662.5M | 901.1M | 1.3B | 796.7M | 836.5M | |
Cash And Short Term Investments | 3.8B | 6.7B | 7.5B | 10.8B | 11.2B | 11.8B | |
Common Stock Shares Outstanding | 260.7M | 263.4M | 259.9M | 259.1M | 260.5M | 153.1M | |
Liabilities And Stockholders Equity | 8.3B | 11.8B | 13.4B | 18.2B | 22.7B | 23.9B | |
Non Current Liabilities Total | 1.0B | 1.5B | 1.5B | 1.8B | 1.6B | 1.7B | |
Other Current Assets | 213.5M | 308.4M | 187.2M | 74.4M | 620.5M | 651.5M | |
Other Stockholder Equity | 7.9B | 7.9B | 6.9B | 7.4B | 7.4B | 7.8B | |
Total Liab | 2.2B | 3.1B | 3.3B | 4.2B | 5.1B | 5.4B | |
Total Current Assets | 4.6B | 7.8B | 9.0B | 12.7B | 14.1B | 14.9B | |
Short Term Debt | 30.3M | 42.4M | 46.9M | 89.4M | 83.7M | 51.0M | |
Accounts Payable | 87.6M | 155.1M | 195M | 303.9M | 364.9M | 383.1M | |
Property Plant And Equipment Gross | 745.1M | 958.5M | 2.3B | 2.5B | 2.6B | 2.8B | |
Accumulated Other Comprehensive Income | (2.0M) | (68.5M) | 15.9M | 800K | (14.3M) | (13.6M) | |
Net Receivables | 633.5M | 885.4M | 1.1B | 1.4B | 1.6B | 1.6B | |
Common Stock Total Equity | 2.6M | 2.6M | 2.5M | 2.6M | 3.0M | 1.9M | |
Common Stock | 2.6M | 2.6M | 2.5M | 2.6M | 3.0M | 2.0M | |
Other Assets | 1.2B | 587.0M | 986.9M | 1.4B | 1.6B | 1.7B | |
Short Term Investments | 699.0M | 670.7M | 729.9M | 274.5M | 849.2M | 579.6M | |
Property Plant Equipment | 833.3M | 958.5M | 1.1B | 1.5B | 1.7B | 1.8B | |
Other Liab | 275.5M | 923.4M | 902.2M | 685.8M | 788.7M | 828.1M | |
Current Deferred Revenue | 62.3M | 191.5M | 171.7M | 159.6M | 170.3M | 118.8M | |
Inventory | 167.5M | 280.8M | 353.1M | 460.6M | 738.8M | 775.7M | |
Net Tangible Assets | 4.7B | 7.3B | 8.7B | 12.2B | 14.1B | 14.8B | |
Retained Earnings Total Equity | (1.9B) | 858.7M | 3.2B | 6.5B | 7.5B | 7.9B | |
Long Term Debt Total | 583.9M | 581.6M | 538.6M | 539.0M | 619.9M | 632.6M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.MSFT | Microsoft | |
CRM | Salesforce | |
GOOG | Alphabet Inc Class C |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for Vertex Stock analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |
Is Vertex Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.181 | Earnings Share 13.9 | Revenue Per Share 38.297 | Quarterly Revenue Growth 0.093 | Return On Assets 0.1317 |
The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vertex Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.